Eagle Pharmaceuticals (NASDAQ: EGRX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-08 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 3.880 | 4.040 | 0.1600 | ||||
REV | 123.330M | 115.874M | -7.456M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Eagle Pharmaceuticals (NASDAQ: EGRX) through any online brokerage.
Other companies in Eagle Pharmaceuticals’s space includes: IDEAYA Biosciences (NASDAQ:IDYA), Cogent Biosciences (NASDAQ:COGT), Immatics (NASDAQ:IMTX), Adicet Bio (NASDAQ:ACET) and TG Therapeutics (NASDAQ:TGTX).
The latest price target for Eagle Pharmaceuticals (NASDAQ: EGRX) was reported by Cantor Fitzgerald on Monday, March 2, 2020. The analyst firm set a price target for 46.00 expecting EGRX to fall to within 12 months (a possible -1.48% downside). 0 analyst firms have reported ratings in the last year.
The stock price for Eagle Pharmaceuticals (NASDAQ: EGRX) is $46.69 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Eagle Pharmaceuticals.
Eagle Pharmaceuticals’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Eagle Pharmaceuticals.
Eagle Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.